论文部分内容阅读
目的研究危重患者的血小板活化标志物P-选择素(CD62P)、血小板膜糖蛋白Ⅱb/Ⅲa(PAC-1)的变化。方法 68例患者根据全身炎症反应综合征(SIRS)和多脏器功能不全(MODS)诊断标准,将患者分为无SIRS组、SIRS组和MODS组。应用APACHEⅡ评分系统分别评分;应用HEMACELL Plus全自动血细胞分析仪通过阻抗法进行血小板的计数;应用流式细胞仪分别检测3组CD62P、PAC-1。结果无SIRS组、SIRS组、MODS组患者CD62P、PAC-1随病情加重,绝对值逐渐增加3,组比较差异有统计学意义(P均<0.01)。结论动态监测危重患者CD62 P、PAC-1水平均可反映危重患者的病情变化。
Objective To study the changes of platelet activating markers P-selectin (CD62P) and platelet glycoprotein Ⅱb / Ⅲa (PAC-1) in critically ill patients. Methods Sixty-eight patients were divided into SIRS-free group, SIRS-treated group and MODS-treated group according to the diagnostic criteria of systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction (MODS). The APACHEⅡscore system was used to score respectively. Platelets were counted by impedance method with HEMACELL Plus automatic hematology analyzer. Three groups of CD62P and PAC-1 were detected by flow cytometry. Results In the patients without SIRS, SIRS and MODS, the absolute values of CD62P and PAC-1 increased with the increase of their severity. The difference between the two groups was statistically significant (P <0.01). Conclusion Dynamic monitoring of critically ill patients with CD62P, PAC-1 levels can reflect the changes in critical patients.